PBS updates

Relaban (Rivaroxaban)

Rivaroxaban 20 mg capsule, 28 · ORAL · PBS code 14994E

STREAMLINED

What it costs

AU$26.66 PBS-determined price per 56 units

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

  • • First listed on the PBS: 2025-09-01.
  • • Repeats: 5.
  • • PBS program: GE.
Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Deep vein thrombosis


Continuing treatment


The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND

Patient must have confirmed acute symptomatic deep vein thrombosis; AND

Patient must not have symptomatic pulmonary embolism.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Prevention of recurrent venous thromboembolism


Continuing treatment


The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND

Patient must have a history of venous thromboembolism.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Pulmonary embolism


Continuing treatment


The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND

Patient must have confirmed acute symptomatic pulmonary embolism.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Prevention of stroke or systemic embolism


The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND

Patient must have non-valvular atrial fibrillation; AND

Patient must have one or more risk factors for developing stroke or systemic embolism.

Risk factors for developing stroke or systemic ischaemic embolism are:

(i) Prior stroke (ischaemic or unknown type), transient ischaemic attack or non-central nervous system (CNS) systemic embolism;

(ii) age 75 years or older;

(iii) hypertension;

(iv) diabetes mellitus;

(v) heart failure and/or left ventricular ejection fraction 35% or less.

Sponsor: Nova Pharmaceuticals Australasia Pty Ltd ABN 87 104 838 440

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.